# Auspex Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/auspex-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.auspexpharma.com
- Total disclosed funding: $63M
- Latest round: Series E (Dec 20, 2013)
- Investors on record: 7

## About

Auspex Pharmaceuticals, Inc. focuses on developing innovative therapies for chronic health conditions, particularly through its specialized drug formulations to improve patient outcomes in neurological and autoimmune disorders.Founded in 2001 and headquartered in the US, Auspex Pharmaceuticals, Inc. is dedicated to the research and development of biopharmaceuticals. The company underwent a significant transition when it was acquired by Teva Pharmaceuticals in March 2015 for USD 3.5 billion, following their IPO in February 2014, where they raised USD 108.90 mn.Auspex Pharmaceuticals specializes in innovative biopharmaceuticals aimed at treating chronic disorders. Their portfolio includes medications for various conditions, including AJOVY® (fremanezumab) for migraine prevention and LUPKYNIS™ (voclosporin) for lupus nephritis, catering to healthcare providers and pharmacies globally across North America, Europe, and Asia.In 2014, Auspex Pharmaceuticals reported an EBITDA of USD -49.14 mn. The company's revenue generation largely relies on B2B sales to healthcare providers and retailers, supplemented by direct-to-consumer strategies, ensuring extensive distribution of their products.Auspex Pharmaceuticals plans to leverage the recent acquisition funding by Teva Pharmaceuticals to expand its product line and enhance market access. Following their IPO in February 2014 that raised USD 108.90 mn, the company is positioned to explore additional therapies and reach new markets, focusing on innovative solutions for neurological and autoimmune conditions. Teva's acquisition in May 2015 will support these strategic initiatives, ensuring a robust pipeline for future product launches.

## Funding rounds

- Series E, Dec 20, 2013, $20M — Thomas, McNerney & Partners, Presidio Partners, Panorama Capital, Costa Verde Capital, Deerfield Management, BioMed Ventures
- Series D, Oct 31, 2012, $17M — Thomas, McNerney & Partners, Presidio Partners, Panorama Capital, Sloan Biotech Fund
- Series C, Oct 13, 2010, $12M — Thomas, McNerney & Partners, Presidio Partners, Sloan Biotech Fund
- Series B, May 7, 2008, $14M — Thomas, McNerney & Partners, Presidio Partners, Costa Verde Capital

## Investors

- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series B, Series C, Series D, Series E
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series B, Series C, Series D, Series E
- Costa Verde Capital — Series B, Series E
- Sloan Biotech Fund — Series C, Series D
- Panorama Capital — Series D, Series E
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series E
- BioMed Ventures — Series E